PFE
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate...
Read moreDetails
3 Reasons to Buy Pfizer Stock Like There’s No Tomorrow
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents protecting their proprietary...
Read moreDetails
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. NYSE: PFE stock is trading back down near its pandemic lows. Every time it attempts to...
Read moreDetails
25 Worst Stocks to Own in January
As President-elect Donald Trump prepares for his inauguration, his administration is gearing up to roll out significant policy shifts.
Read moreDetails
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
Pfizer (PFE 0.23%) became a stock market star in early pandemic days as it brought the first coronavirus vaccine to...
Read moreDetails
Pfizer (PFE) Suffers a Larger Drop Than the General Market: Key Insights
Pfizer (PFE) closed the most recent trading day at $26.56, moving -0.67% from the previous trading session.
Read moreDetails